Cyclophosphamide protection in nzb/nzw disease. Mechanisms and therapeutic regimens
- 1 January 1976
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 19 (1), 49-55
- https://doi.org/10.1002/art.1780190108
Abstract
Regular administration of cyclophosphamide to NZB/NZW female mice effectively protects against the nephritis that is thought to be a model for human SLE nephritis. Reductions in serologic, histologic, and immunofluorescent parameters of the disease are correlated. Intermittent as well as continuous administration of the drug is effective without the development of leukopenia. Possible mechanisms of drug action and a modified approach to therapy of immune complex disease are discussed.This publication has 23 references indexed in Scilit:
- Prevention of Murine Lupus Nephritis by Carrier-Dependent Induction of Immunologic Tolerance to Denatured DNAScience, 1973
- Efficacy of immunosuppressive drugs in rheumatic diseasesArthritis & Rheumatism, 1973
- Toxicity of immunosuppressive drugs in manArthritis & Rheumatism, 1973
- Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexateArthritis & Rheumatism, 1973
- CYCLOPHOSPHAMIDE THERAPY AND STERILITYThe Lancet, 1972
- Therapeutic studies in NZB/W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisoloneArthritis & Rheumatism, 1972
- Immunosuppressive therapy. Guidelines for drug dosage. Depression of bone marrow granulocyte reserves in systemic lupus erythematosusArthritis & Rheumatism, 1972
- Multiple late complications of therapy with cyclophosphamide, including ovarian destructionThe American Journal of Medicine, 1971
- AutoantibodiesThe Lancet Healthy Longevity, 1970
- A procedure for the isolation of deoxyribonucleic acid from micro-organismsJournal of Molecular Biology, 1961